{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:13:26Z","timestamp":1793614406253,"version":"4.5.0"},"reference-count":431,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C67321\/A29060"],"award-info":[{"award-number":["C67321\/A29060"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017458","name":"Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center","doi-asserted-by":"publisher","award":["5T32CA160001"],"award-info":[{"award-number":["5T32CA160001"]}],"id":[{"id":"10.13039\/100017458","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["P01 CA106451"],"award-info":[{"award-number":["P01 CA106451"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["U01CA0290479"],"award-info":[{"award-number":["U01CA0290479"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["P30 CA023100"],"award-info":[{"award-number":["P30 CA023100"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["R01DE026644"],"award-info":[{"award-number":["R01DE026644"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["P50 CA097007"],"award-info":[{"award-number":["P50 CA097007"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["PCT\/US2022\/015363"],"award-info":[{"award-number":["PCT\/US2022\/015363"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["63\/483,237"],"award-info":[{"award-number":["63\/483,237"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001033","name":"Jane Coffin Childs Memorial Fund for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U2CCA271898"],"award-info":[{"award-number":["1U2CCA271898"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["R37CA248631"],"award-info":[{"award-number":["R37CA248631"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1I50CU000157"],"award-info":[{"award-number":["1I50CU000157"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["R01HG012590"],"award-info":[{"award-number":["R01HG012590"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T30DT0963"],"award-info":[{"award-number":["T30DT0963"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K99 CA266939"],"award-info":[{"award-number":["K99 CA266939"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jtho.2024.12.020","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T11:52:19Z","timestamp":1735041139000},"page":"1177-1236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9\/10 Induction"],"prefix":"10.1016","volume":"20","author":[{"given":"Xin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"William","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaloyan M.","family":"Tsanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jui","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco M.","family":"Barriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trifas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Dubinett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2024.12.020_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","article-title":"Overlapping and non-overlapping indications for checkpoint inhibitors in the US","volume":"42","author":"Paul","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.22.02437","article-title":"Flashback foreword: single-agent anti-programmed cell death Protein 1 therapy for refractory solid tumors","volume":"41","author":"Maki","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","article-title":"Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","volume":"36","author":"Rizvi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib4","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1158\/1078-0432.CCR-23-1207","article-title":"Clinical and molecular features of long-term response to immune checkpoint inhibitors in atients with advanced non-small cell lung cancer","volume":"29","author":"Thummalapalli","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib5","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death Ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-018-0489-5","article-title":"Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors","volume":"7","author":"Conroy","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib8","first-page":"835","article-title":"Chromosomal copy number variation predicts EGFR-TKI response and prognosis for patients with non-small cell lung cancer","volume":"16","author":"He","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib9","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib10","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109760","article-title":"Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis","volume":"9","author":"Linsley","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib12","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.1038\/s41467-024-52285-7","article-title":"Proteogenomic characterization of skull-base chordoma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-22-1427","article-title":"Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways","volume":"13","author":"Spain","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaoncol.2023.4853","article-title":"Nivolumab for patients with high-risk oral leukoplakia: a nonrandomized controlled trial","volume":"10","author":"Hanna","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.it.2022.03.003","article-title":"All is not lost: learning from 9p21 loss in cancer","volume":"43","author":"Spiliopoulou","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41586-024-08509-3","article-title":"SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO","volume":"638","author":"Borck","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s43018-024-00876-0","article-title":"Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer","volume":"6","author":"Ganguli","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41467-020-20469-6","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib21","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive biomarkers for immunotherapy in lung cancer: perspective from the International Association for the Study of Lung Cancer pathology committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib22","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib24","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib26","article-title":"Is tumor mutational burden predictive of response to immunotherapy?","volume":"12","author":"Gurjao","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.jtho.2024.12.020_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf8399","article-title":"Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy","volume":"355","author":"Davoli","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib28","article-title":"Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma","volume":"14","author":"Luo","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2024.12.020_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj9905","article-title":"A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer","volume":"16","author":"Miller","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","article-title":"The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer pathology committee","volume":"15","author":"Sholl","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13073-020-00743-4","article-title":"MHC-I genotype and tumor mutational burden predict response to immunotherapy","volume":"12","author":"Goodman","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamaoncol.2018.7098","article-title":"Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169823","article-title":"Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma","volume":"133","author":"Valero","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2024.12.020_bib39","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2024.12.020_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ado9746","article-title":"Prediction of immunotherapy response using mutations to cancer protein assemblies","volume":"10","author":"Kong","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtho.2024.12.020_bib41","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.cell.2024.01.027","article-title":"Pan-cancer proteogenomics characterization of tumor immunity","volume":"187","author":"Petralia","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75227","article-title":"Proteogenomic analysis of cancer aneuploidy and normal tissues reveals divergent modes of gene regulation across cellular pathways","volume":"11","author":"Cheng","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.jtho.2024.12.020_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12920-017-0308-8","article-title":"Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types","volume":"10","author":"Budczies","year":"2017","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jtho.2024.12.020_bib44","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/gcc.22468","article-title":"Mutation patterns in genes encoding interferon signaling and antigen presentation: a pan-cancer survey with implications for the use of immune checkpoint inhibitors","volume":"56","author":"Budczies","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/1878-0261.12891","article-title":"Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"15","author":"Frigola","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.02.037","article-title":"Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns","author":"Sack","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib48","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-17-3509","article-title":"A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations","volume":"24","author":"Tamborero","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ccell.2018.03.007","article-title":"Genomic and functional approaches to understanding cancer aneuploidy","volume":"33","author":"Taylor","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022655118","article-title":"Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss","volume":"118","author":"William","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib51","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213835119","article-title":"Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/jnci\/djx271","article-title":"Tumor CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance","volume":"110","author":"Horn","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2024.12.020_bib54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib55","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib56","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/cncr.34607","article-title":"Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort","volume":"129","author":"William","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13073-022-01138-3","article-title":"Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution","volume":"14","author":"Thol","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","article-title":"Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy","volume":"6","author":"Ebot","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179726","article-title":"Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors","volume":"12","author":"Siemers","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib90","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2020.02.017","article-title":"Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer","volume":"31","author":"Lamberti","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib87","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jtho.2023.05.019","article-title":"Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2019.12.128","article-title":"Frequent homozygous deletions of type I interferon genes in pleural mesothelioma confer sensitivity to oncolytic measles virus","volume":"15","author":"Delaunay","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib91","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-023-02711-3","article-title":"B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma","volume":"42","author":"Cui","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007823","article-title":"Association of a gene-expression subtype to outcome and treatment response in patients with recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab","volume":"12","author":"Serafini","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib68","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib77","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/s41586-023-06421-w","article-title":"Interferon-\u03b5 is a tumour suppressor and restricts ovarian cancer","volume":"620","author":"Marks","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib80","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ccell.2023.02.005","article-title":"Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment","volume":"41","author":"Klement","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2024.102456","article-title":"IFN\u03b5, IFN\u03c9 and IFN\u03bb: interferons defending the mucosa","volume":"89","author":"Chuah","year":"2024","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s44321-023-00018-6","article-title":"Interferon-epsilon is a novel regulator of NK cell responses in the uterus","volume":"16","author":"Mayall","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib83","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929005","article-title":"Double-edged effects of interferons on the regulation of cancer-immunity cycle","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib85","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1038\/s41467-022-32567-8","article-title":"Temporally restricted activation of IFN\u03b2 signaling underlies response to immune checkpoint therapy in mice","volume":"13","author":"Zemek","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib92","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050692","article-title":"Influence of genetic variants in type I interferon genes on melanoma survival and therapy","volume":"7","author":"Lenci","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib78","article-title":"Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection","author":"Broomfield","year":"2024","journal-title":"BioRxiv"},{"key":"10.1016\/j.jtho.2024.12.020_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77285-x","article-title":"Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma","volume":"14","author":"V\u00edzkeleti","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib95","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3389\/fimmu.2020.00542","article-title":"Diverse anti-tumor immune potential driven by individual IFN\u03b1 subtypes","volume":"11","author":"Buzzai","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib96","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib97","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib98","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007313","article-title":"RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib99","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccr.2013.11.011","article-title":"Hepatic RIG-I predicts survival and interferon-\u03b1 therapeutic response in hepatocellular carcinoma","volume":"25","author":"Hou","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib100","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8943","article-title":"RIG-I activation is critical for responsiveness to checkpoint blockade","volume":"4","author":"Heidegger","year":"2019","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138726","article-title":"The relationship of immune cell signatures to patient survival varies within and between tumor types","volume":"10","author":"Linsley","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib102","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/gcc.22365","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival","volume":"55","author":"Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib103","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00262-020-02825-z","article-title":"PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung","volume":"70","author":"Goldmann","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2024.12.020_bib104","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1078-0432.CCR-16-2128","article-title":"Immune cytolytic activity stratifies molecular subsets of human pancreatic cancer","volume":"23","author":"Balli","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib105","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00262-021-02918-3","article-title":"Distinct genomic features across cytolytic subgroups in skin melanoma","volume":"70","author":"Roufas","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jtho.2024.12.020_bib69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","article-title":"CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis","volume":"19","author":"Yang","year":"2020","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib107","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1158\/1078-0432.CCR-18-3991","article-title":"Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity","volume":"25","author":"Tanegashima","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","article-title":"Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines","volume":"86","author":"Zhang","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.jtho.2024.12.020_bib108","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41571-024-00979-8","article-title":"Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions","volume":"22","author":"Wang","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib61","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41467-023-42400-5","article-title":"Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial","volume":"14","author":"Pouyiourou","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12935-024-03412-3","article-title":"Blood-based molecular and cellular biomarkers of early response to neoadjuvant PD-1 blockade in patients with non-small cell lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.jtho.2024.12.020_bib179","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.oraloncology.2019.06.032","article-title":"Immune profiles in primary squamous cell carcinoma of the head and neck","volume":"96","author":"Saloura","year":"2019","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib109","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/s41586-024-08398-6","article-title":"Synthetic lethality of mRNA quality control complexes in cancer","volume":"638","author":"Prindle","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib75","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib110","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib112","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245287","article-title":"CTLA-4 blockade and interferon-\u03b1 induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma","volume":"16","author":"Khunger","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib113","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.3390\/cancers14246220","article-title":"Comprehensive analysis of DMRT3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma","volume":"14","author":"Yang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.12.020_bib114","article-title":"Comprehensive analysis identifies and validates the tumor microenvironment subtypes to predict anti-tumor therapy efficacy in hepatocellular carcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib59","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib60","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","article-title":"Prevalent homozygous deletions of Type I interferon and defensin genes in human cancers associate with immunotherapy resistance","volume":"24","author":"Ye","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib62","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1878-0261.13206","article-title":"Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma","volume":"16","author":"Peng","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98414-w","article-title":"Integrated genomics point to immune vulnerabilities in pleural mesothelioma","volume":"11","author":"Nastase","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.695770","article-title":"Homozygous co-deletion of Type I interferons and CDKN2A genes in thoracic cancers: potential consequences for therapy","volume":"11","author":"Grard","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107963","article-title":"MTAP as an emerging biomarker in thoracic malignancies","volume":"197","author":"Brune","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib67","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cell.2018.08.027","article-title":"The multifaceted role of chromosomal instability in cancer and its microenvironment","volume":"174","author":"Bakhoum","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib71","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jmoldx.2011.06.003","article-title":"Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays","volume":"13","author":"Crespo","year":"2011","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jtho.2024.12.020_bib72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jcp-2023-209341","article-title":"Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers","volume":"78","author":"Mauri","year":"2025","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jtho.2024.12.020_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2025.04.005","article-title":"Targeting vulnerabilities of aneuploid cells for cancer therapy","author":"Zerbib","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib73","doi-asserted-by":"crossref","first-page":"1065029","DOI":"10.3389\/fphar.2022.1065029","article-title":"Deciphering the role of DOCK8 in tumorigenesis by regulating immunity and the application of nanotechnology in DOCK8 deficiency therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtho.2024.12.020_bib74","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1053\/j.gastro.2015.12.032","article-title":"Microsatellite alterations with allelic loss at 9p24.2 signify less-aggressive colorectal cancer metastasis","volume":"150","author":"Koi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtho.2024.12.020_bib76","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/cas.16119","article-title":"Integration of CD4+ T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer","volume":"115","author":"Liu","year":"2024","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib84","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/carcin\/bgu203","article-title":"Genetic polymorphisms in the 9p21 region associated with risk of multiple cancers","volume":"35","author":"Li","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2024.12.020_bib86","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-22-0886","article-title":"Genomic instability and protumoral inflammation are associated with primary resistance to anti-PD-1 + antiangiogenesis in malignant pleural mesothelioma","volume":"13","author":"Danlos","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib203","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/ijms24021294","article-title":"Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers","volume":"24","author":"Spiliopoulou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib157","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.13587","article-title":"MTAP deficiency contributes to immune landscape remodelling and tumour evasion","volume":"168","author":"Chang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib163","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib115","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib117","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/imm.13587","article-title":"MTAP deficiency contributes to immune landscape remodelling and tumour evasion","volume":"168","author":"Chang","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib119","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","article-title":"Molecular determinants of response to PD-L1 blockade across tumor types","volume":"12","author":"Banchereau","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib120","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib121","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41467-017-01018-0","article-title":"Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers","volume":"8","author":"Ock","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib122","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1101\/gr.212225.116","article-title":"Pan-cancer analysis distinguishes transcriptional changes of aneuploidy from proliferation","volume":"27","author":"Buccitelli","year":"2017","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib123","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1657374","article-title":"Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion","volume":"8","author":"Tripathi","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.297.5581.565","article-title":"Connecting chromosomes, crisis, and cancer","volume":"297","author":"Maser","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib126","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib127","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib128","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cell.2012.11.043","article-title":"Gene copy-number alterations: a cost-benefit analysis","volume":"152","author":"Tang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41576-024-00761-7","article-title":"Chromosomal instability as a driver of cancer progression","volume":"26","author":"Chen","year":"2025","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib130","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib116","article-title":"Molecular characterization of mesothelioma: impact of histologic type and site of origin on molecular landscape","volume":"6","author":"Dagogo-Jack","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib131","article-title":"Pan-cancer analysis of chromothripsis-related gene expression patterns indicates an association with tumor immune and therapeutic agent responses","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib132","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(65)90131-5","article-title":"Minute chromatin bodies in malignant tumours of childhood","volume":"1","author":"Cox","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2024.12.020_bib133","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1038\/s41598-022-07530-8","article-title":"Extrachromosomal DNA formation enables tumor immune escape potentially through regulating antigen presentation gene expression","volume":"12","author":"Wu","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib134","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41467-024-45479-6","article-title":"Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41586-023-05937-5","article-title":"Extrachromosomal DNA in the cancerous transformation of Barrett\u2018s oesophagus","volume":"616","author":"Luebeck","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib136","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41568-024-00744-0","article-title":"Defining precancer: a grand challenge for the cancer community","volume":"24","author":"Faupel-Badger","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41422-024-01054-8","article-title":"Modern biology of extrachromosomal DNA: a decade-long voyage of discovery","volume":"35","author":"Yang","year":"2025","journal-title":"Cell Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib138","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41586-024-08107-3","article-title":"Origins and impact of extrachromosomal DNA","volume":"635","author":"Bailey","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib139","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.88895.3","article-title":"Transcriptional immune suppression and up-regulation of double-stranded DNA damage and repair repertoires in ecDNA-containing tumors","volume":"12","author":"Lin","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.jtho.2024.12.020_bib140","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3390\/cells11091530","article-title":"Consequences of chromosome loss: why Do cells need each chromosome twice?","volume":"11","author":"Chunduri","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jtho.2024.12.020_bib141","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib142","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An immunosurveillance mechanism controls cancer cell ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib143","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1526613","article-title":"Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden","volume":"7","author":"Budczies","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib144","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1158\/1078-0432.CCR-20-1497","article-title":"Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma","volume":"26","author":"Bassaganyas","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","article-title":"Improved prediction of immune checkpoint blockade efficacy across multiple cancer types","volume":"40","author":"Chowell","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jtho.2024.12.020_bib146","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/s43018-022-00467-x","article-title":"Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade","volume":"3","author":"Spurr","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib147","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2021.11.012","article-title":"Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance","volume":"40","author":"Newell","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib148","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1200\/PO.20.00069","article-title":"BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer","volume":"4","author":"Liu","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib149","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-19-0558","article-title":"Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer","volume":"25","author":"Liu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/2767-9764.CRC-22-0073","article-title":"Landscape of genetic alterations underlying hallmark signature changes in cancer reveals TP53 aneuploidy-driven metabolic reprogramming","volume":"3","author":"McClure","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib151","article-title":"Identification and validation of immune molecular subtypes in pancreatic ductal adenocarcinoma: implications for prognosis and immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib152","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000374","article-title":"Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer","volume":"8","author":"Lu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib153","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtho.2024.12.020_bib154","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41591-021-01331-8","article-title":"Evolution of delayed resistance to immunotherapy in a melanoma responder","volume":"27","author":"Liu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.816517","article-title":"Modulation of Type I interferon responses to influence tumor-immune cross talk in PDAC","volume":"10","author":"Cattolico","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib156","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-23-0251","article-title":"Multi-omics analysis reveals immune features associated with immunotherapy benefit in patients with squamous cell lung cancer from Phase III lung-MAP S1400I trial","volume":"30","author":"Parra","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib158","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41523-021-00352-3","article-title":"Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study","volume":"7","author":"Zerdes","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib159","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jamaoncol.2017.2140","article-title":"Association between genomic metrics and immune infiltration in triple-negative breast cancer","volume":"3","author":"Karn","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib160","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1038\/s41467-021-25432-7","article-title":"Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity","volume":"12","author":"Cindy Yang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib161","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98966-x","article-title":"Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy","volume":"11","author":"Zheng","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib162","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1038\/s41467-024-53390-3","article-title":"Hallmarks of a genomically distinct subclass of head and neck cancer","volume":"15","author":"Muijlwijk","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib164","doi-asserted-by":"crossref","first-page":"7187","DOI":"10.1038\/s41467-024-49842-5","article-title":"A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib165","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007618","article-title":"Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer","volume":"11","author":"Alessi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib167","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1038\/s41467-019-12159-9","article-title":"DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load","volume":"10","author":"Jung","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib168","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib169","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","article-title":"Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer","volume":"55","author":"Ravi","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib170","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/1535-7163.MCT-18-0535","article-title":"Genome-wide sequencing of cell-free DNA identifies copy-number alterations that can be used for monitoring response to immunotherapy in cancer patients","volume":"18","author":"Jensen","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.12.020_bib171","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3390\/cancers16051027","article-title":"Comparison of immunotherapy versus targeted therapy effectiveness in BRAF-mutant melanoma patients and use of cGAS expression and aneuploidy as potential prognostic biomarkers","volume":"16","author":"Garrison","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.12.020_bib172","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39217","article-title":"Systematic identification of mutations and copy number alterations associated with cancer patient prognosis","volume":"7","author":"Smith","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.jtho.2024.12.020_bib173","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/0008-5472.CAN-16-3478","article-title":"Immune gene expression is associated with genomic aberrations in breast cancer","volume":"77","author":"Safonov","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib174","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/JS9.0000000000002077","article-title":"Identification of genomic alteration and prognosis using pathomics-based artificial intelligence in oral leukoplakia and head and neck squamous cell carcinoma: a multicenter experimental study","volume":"111","author":"Cai","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.jtho.2024.12.020_bib175","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41576-019-0171-x","article-title":"Context is everything: aneuploidy in cancer","volume":"21","author":"Ben-David","year":"2020","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib176","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamaoncol.2015.4364","article-title":"Erlotinib and the risk of oral cancer: the erlotinib prevention of oral cancer (EPOC) randomized clinical trial","volume":"2","author":"William","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib177","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib180","article-title":"Selection forces underlying aneuploidy patterns in cancer","volume":"11","author":"Klockner","year":"2024","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib181","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ccell.2018.03.018","article-title":"Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib182","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3390\/cancers16040732","article-title":"Tumor copy number alteration burden as a predictor for resistance to immune checkpoint blockade across different cancer types","volume":"16","author":"Asleh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.12.020_bib183","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41588-022-01235-4","article-title":"Tumor aneuploidy predicts survival following immunotherapy across multiple cancers","volume":"54","author":"Spurr","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib184","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib185","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.7150\/thno.81350","article-title":"Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy","volume":"13","author":"Chu","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jtho.2024.12.020_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.895961","article-title":"Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity","volume":"13","author":"Kuang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib187","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib188","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41467-020-15538-9","article-title":"Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma","volume":"11","author":"Mitra","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib178","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib189","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13048-024-01356-w","article-title":"Aneuploid serves as a prognostic marker and favors immunosuppressive microenvironment in ovarian cancer","volume":"17","author":"Du","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib190","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1200\/JCO.23.02641","article-title":"Deep learning artificial intelligence predicts homologous recombination deficiency and platinum response from histologic slides","volume":"42","author":"Bergstrom","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib191","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/2767-9764.CRC-22-0047","article-title":"Classifying cGAS-STING activity links chromosomal instability with immunotherapy response in metastatic bladder cancer","volume":"2","author":"Soka\u010d","year":"2022","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib192","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10577-023-09737-5","article-title":"Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies","volume":"31","author":"Andrade","year":"2023","journal-title":"Chromosome Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00609-z","article-title":"cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer","volume":"10","author":"Chen","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib194","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/1878-0261.13196","article-title":"Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer","volume":"16","author":"Mendelaar","year":"2022","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102394","article-title":"Deep learning predicts chromosomal instability from histopathology images","volume":"24","author":"Xu","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jtho.2024.12.020_bib196","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41416-019-0686-0","article-title":"A model combining clinical and genomic factors to predict response to PD-1\/PD-L1 blockade in advanced urothelial carcinoma","volume":"122","author":"Nassar","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.988691","article-title":"Causes, consequences and clinical significance of aneuploidy across melanoma subtypes","volume":"12","author":"Shteinman","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib198","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41698-023-00408-6","article-title":"Optimizing cancer immunotherapy response prediction by tumor aneuploidy score and fraction of copy number alterations","volume":"7","author":"Chang","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib199","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1093\/bioinformatics\/btaa980","article-title":"Quantification of aneuploidy in targeted sequencing data using ASCETS","volume":"37","author":"Spurr","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2024.12.020_bib200","author":"Choudhury"},{"key":"10.1016\/j.jtho.2024.12.020_bib201","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1158\/2767-9764.CRC-23-0564","article-title":"Noninvasive lung cancer subtype classification using tumor-derived signatures and cfDNA Methylome","volume":"4","author":"Li","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib202","article-title":"Combined transcriptome and circulating tumor DNA longitudinal biomarker analysis associates with clinical outcomes in advanced solid tumors treated with pembrolizumab","volume":"8","author":"Hernando-Calvo","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib204","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41591-022-01754-x","article-title":"Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial","volume":"28","author":"Kim","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib205","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/s41591-022-01933-w","article-title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","volume":"28","author":"Peters","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib206","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12916-021-02075-5","article-title":"Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC","volume":"19","author":"Sun","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib207","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41392-023-01672-5","article-title":"Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer","volume":"8","author":"Han","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2024.12.020_bib208","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41467-020-14286-0","article-title":"Chromosome arm aneuploidies shape tumour evolution and drug response","volume":"11","author":"Shukla","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib209","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.118","article-title":"Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response","volume":"10","author":"Li","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745945","article-title":"CD8+ T cell-based molecular classification with heterogeneous immunogenomic landscapes and clinical significance of clear cell renal cell carcinoma","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib211","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/s41588-024-01916-2","article-title":"Aneuploidy as a driver of human cancer","volume":"56","author":"Sdeor","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib212","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.semradonc.2021.09.002","article-title":"Chromosome missegregation as a modulator of radiation sensitivity","volume":"32","author":"Cosper","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib213","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd4811","article-title":"Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel","volume":"13","author":"Scribano","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib214","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1158\/0008-5472.CAN-24-0169","article-title":"Patterns of aneuploidy and signaling consequences in cancer","volume":"84","author":"Zhakula-Kostadinova","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1462496","article-title":"Genomic instability as a driver and suppressor of anti-tumor immunity","volume":"15","author":"Requesens","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib216","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42003-021-01657-6","article-title":"Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer","volume":"4","author":"Jia","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib217","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib218","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/biomedicines9101349","article-title":"Irradiation mediates IFN\u03b1 and CXCL9 expression in non-small cell lung cancer to stimulate CD8+ T cells activity and migration toward tumors","volume":"9","author":"Cheng","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtho.2024.12.020_bib219","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib220","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/bjc.2016.166","article-title":"Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer","volume":"115","author":"Sridharan","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib221","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41586-022-04738-6","article-title":"Signatures of copy number alterations in human cancer","volume":"606","author":"Steele","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib222","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1158\/1078-0432.CCR-08-1463","article-title":"Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications","volume":"15","author":"Klussmann","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib223","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/ng.3051","article-title":"Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss","volume":"46","author":"Gross","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib224","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3390\/v16040501","article-title":"Human papillomavirus-induced chromosomal instability and aneuploidy in squamous cell cancers","volume":"16","author":"Mallick","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jtho.2024.12.020_bib225","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41586-023-06266-3","article-title":"Cancer aneuploidies are shaped primarily by effects on tumour fitness","volume":"619","author":"Shih","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cels.2021.10.001","article-title":"Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer","volume":"13","author":"Ciani","year":"2022","journal-title":"Cell Syst"},{"key":"10.1016\/j.jtho.2024.12.020_bib227","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2016.03.025","article-title":"Integrated genomics for pinpointing survival loci within arm-level somatic copy number alterations","volume":"29","author":"Roy","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib228","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1006665","article-title":"Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden","volume":"13","author":"Georgoulias","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib229","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib230","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","article-title":"Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma","volume":"25","author":"Yu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib231","first-page":"2449","article-title":"Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density","volume":"18","author":"Wohlfarth","year":"2024","journal-title":"Mol Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib232","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.721676","article-title":"CDKN2B-AS1 promotes malignancy as a novel prognosis-related molecular marker in the endometrial cancer immune microenvironment","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib233","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1038\/s41467-019-13460-3","article-title":"Genomic and immune profiling of pre-invasive lung adenocarcinoma","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib234","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.ccell.2023.07.007","article-title":"Proteogenomic insights suggest druggable pathways in endometrial carcinoma","volume":"41","author":"Dou","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib235","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","article-title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","volume":"619","author":"Abdel-Hafiz","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib236","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-023-05923-x","article-title":"Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats","volume":"616","author":"Li","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib237","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1158\/1078-0432.CCR-19-3997","article-title":"Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer","volume":"26","author":"Feng","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib238","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1148389","article-title":"The role of p53 in anti-tumor immunity and response to immunotherapy","volume":"10","author":"Carlsen","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jtho.2024.12.020_bib239","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11033-023-09097-7","article-title":"TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress","volume":"51","author":"Zhu","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib240","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0696-682","article-title":"Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment","volume":"2","author":"Mao","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109632","article-title":"High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy","volume":"27","author":"Fujiwara","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jtho.2024.12.020_bib242","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.18632\/aging.202640","article-title":"Suppression of p16 alleviates the senescence-associated secretory phenotype","volume":"13","author":"Buj","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.jtho.2024.12.020_bib243","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1101\/gad.343129.120","article-title":"Senescence and the SASP: many therapeutic avenues","volume":"34","author":"Birch","year":"2020","journal-title":"Genes Dev"},{"key":"10.1016\/j.jtho.2024.12.020_bib244","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtho.2024.12.020_bib245","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","article-title":"Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer","volume":"25","author":"Fang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib246","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2020.12.007","article-title":"Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma","volume":"39","author":"Huang","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib247","article-title":"Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma","volume":"2","author":"Liu","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib248","article-title":"Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib249","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004197","article-title":"High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC","volume":"10","author":"Frigola","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib250","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib251","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15440","article-title":"Acquired IFN\u03b3 resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions","volume":"8","author":"Sucker","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib252","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","article-title":"Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors","volume":"50","author":"Miao","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib253","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1038\/s41467-021-26821-8","article-title":"Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib254","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/1078-0432.CCR-20-2984","article-title":"The genetic evolution of treatment-resistant cutaneous, acral, and uveal melanomas","volume":"27","author":"Makohon-Moore","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib255","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","article-title":"Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy","volume":"527","author":"Peng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib256","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I","article-title":"Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line","volume":"30","author":"Bentz","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib257","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib258","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1038\/s41467-024-50830-y","article-title":"Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation","volume":"15","author":"Stokes","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib259","article-title":"Copy number alterations in CDKN2A\/2B and MTAP genes are associated with low MEF2C expression in T-cell acute lymphoblastic leukemia","volume":"14","author":"Kumari","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jtho.2024.12.020_bib260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-024-01976-2","article-title":"rs822336 binding to C\/EBP\u03b2 and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1\/PD-L1 therapy in advanced NSCLC","volume":"23","author":"Polcaro","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib261","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1158\/2326-6066.CIR-24-0164","article-title":"Integrated germline and somatic features reveal divergent immune pathways driving response to immune checkpoint blockade","volume":"12","author":"Sears","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib262","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.18632\/oncotarget.7593","article-title":"CD274\/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity","volume":"7","author":"Straub","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.12.020_bib263","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2024.12.020_bib264","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2018s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib265","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.2023022197","article-title":"Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma","volume":"145","author":"Gottschlich","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2024.12.020_bib266","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2024.12.020_bib267","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2020006464","article-title":"Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell\/histiocyte-rich large B-cell lymphoma","volume":"137","author":"Griffin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2024.12.020_bib268","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006311","article-title":"PD-L1 gene amplification and focality: relationship with protein expression","volume":"11","author":"Jardim","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib269","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","article-title":"Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors","volume":"4","author":"Goodman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib270","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010130","article-title":"Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database","volume":"12","author":"Nakayama","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib271","article-title":"Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression","volume":"9","author":"Huang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib272","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/2159-8290.CD-24-1366","article-title":"Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma","volume":"15","author":"Kader","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib273","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/oncolo\/oyac096","article-title":"Association of CD274 (PD-L1) copy number changes with immune checkpoint inhibitor clinical benefit in non-squamous non-small cell lung cancer","volume":"27","author":"Murugesan","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jtho.2024.12.020_bib274","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-201532","article-title":"CD274 (PD-L1) copy number changes (gain) & response to immune checkpoint blockade therapy in carcinomas of the urinary tract","volume":"7","author":"Gupta","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 Is Upregulated by Simultaneous amplification of the PD-L1 and JAK2 Genes in non-small Cell Lung Cancer","volume":"11","author":"Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib276","doi-asserted-by":"crossref","first-page":"32113","DOI":"10.18632\/oncotarget.8528","article-title":"Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer","volume":"7","author":"Inoue","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2024.12.020_bib277","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11818","article-title":"Evaluation of programmed death ligand 1 (PD-L1) gene amplification and response to nivolumab monotherapy in non-small cell lung cancer","volume":"3","author":"Inoue","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2024.12.020_bib278","doi-asserted-by":"crossref","first-page":"E7769","DOI":"10.1073\/pnas.1607836113","article-title":"Association of PD-1\/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors","volume":"113","author":"Danilova","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib279","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41591-023-02304-9","article-title":"Multi-organ landscape of therapy-resistant melanoma","volume":"29","author":"Liu","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib280","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.molcel.2014.12.030","article-title":"Interferon \u03b1\/\u03b2 enhances the cytotoxic response of MEK inhibition in melanoma","volume":"57","author":"Litvin","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib281","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1038\/s41467-021-25728-8","article-title":"MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I","volume":"12","author":"Br\u00e4gelmann","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib282","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1158\/2159-8290.CD-22-0787","article-title":"Blocking genomic instability prevents acquired resistance to MAPK inhibitor therapy in melanoma","volume":"13","author":"Dharanipragada","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib283","article-title":"MYC activation impairs cell-intrinsic IFN\u03b3 signaling and confers resistance to anti-PD1\/PD-L1 therapy in lung cancer","volume":"4","author":"Alburquerque-Bejar","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib284","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41467-023-36328-z","article-title":"Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer","volume":"14","author":"Hong","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199001113220202","article-title":"Deletions of interferon genes in acute lymphoblastic leukemia","volume":"322","author":"Diaz","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib286","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1073\/pnas.81.9.2665","article-title":"Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization","volume":"81","author":"Carrera","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib287","first-page":"3193","article-title":"Absence of methylthioadenosine phosphorylase in human gliomas","volume":"51","author":"Nobori","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib288","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/368753a0","article-title":"Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers","volume":"368","author":"Nobori","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib289","first-page":"2523","article-title":"Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas","volume":"52","author":"Olopade","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/bj1150241","article-title":"Phosphate-stimulated breakdown of 5\u2019-methylthioadenosine by rat ventral prostate","volume":"115","author":"Pegg","year":"1969","journal-title":"Biochem J"},{"key":"10.1016\/j.jtho.2024.12.020_bib291","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0006-291X(83)91476-6","article-title":"Metabolism to methionine and growth stimulation by 5\u2019-methylthioadenosine and 5\u2019-methylthioinosine in mammalian cells","volume":"112","author":"Carson","year":"1983","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib292","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4684-5637-0_15","article-title":"Human 5\u2019-deoxy-5\u2019-methylthioadenosine phosphorylase: kinetic studies and catalytic mechanism","volume":"250","author":"Zappia","year":"1988","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib293","doi-asserted-by":"crossref","first-page":"7288","DOI":"10.1016\/S0021-9258(18)32175-6","article-title":"Biochemical genetic analysis of the role of methylthioadenosine phosphorylase in a murine lymphoid cell line","volume":"258","author":"Kubota","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtho.2024.12.020_bib294","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jchromb.2008.10.038","article-title":"Quantitative analysis of 5\u2019-deoxy-5\u2019-methylthioadenosine in melanoma cells by liquid chromatography-stable isotope ratio tandem mass spectrometry","volume":"876","author":"Stevens","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib295","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib296","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nri3625","article-title":"New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation","volume":"14","author":"Wells","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib297","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib298","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001936","article-title":"Protein arginine methyltransferase 5 regulates ERK1\/2 signal transduction amplitude and cell fate through CRAF","volume":"4","author":"Andreu-P\u00e9rez","year":"2011","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtho.2024.12.020_bib299","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib300","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(01)00269-0","article-title":"Arginine methylation of STAT1 modulates IFNalpha\/beta-induced transcription","volume":"104","author":"Mowen","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib301","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1016\/j.ejca.2014.07.005","article-title":"The metabolite 5\u2019-methylthioadenosine signals through the adenosine receptor A2B in melanoma","volume":"50","author":"Limm","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib302","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3389\/fimmu.2020.02128","article-title":"The oncometabolite 5\u2019-deoxy-5\u2019-methylthioadenosine blocks multiple signaling pathways of NK cell activation","volume":"11","author":"Jacobs","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib303","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.2100523","article-title":"PRMT5 deficiency enforces the transcriptional and epigenetic programs of Klrg1+CD8+ terminal effector T cells and promotes cancer development","volume":"208","author":"Zheng","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib304","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1184802","article-title":"Suppressive effects of tumor cell-derived 5\u2019-deoxy-5\u2019-methylthioadenosine on human T cells","volume":"5","author":"Henrich","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib305","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41467-021-21804-1","article-title":"Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma","volume":"12","author":"Hung","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib306","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib307","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1074\/jbc.272.7.4359","article-title":"Interference with DNA methyltransferase activity and genome methylation during F9 teratocarcinoma stem cell differentiation induced by polyamine depletion","volume":"272","author":"Frostesj\u00f6","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtho.2024.12.020_bib308","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/j.1600-0625.2010.01072.x","article-title":"Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma","volume":"19","author":"Meyer","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jtho.2024.12.020_bib309","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archderm.142.4.471","article-title":"Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors","volume":"142","author":"Wild","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jtho.2024.12.020_bib310","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/0008-5472.CAN-18-1010","article-title":"MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation","volume":"79","author":"Hansen","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib311","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002271","article-title":"Characterization and prognostic significance of methylthioadenosine phosphorylase deficiency in nasopharyngeal carcinoma","volume":"94","author":"He","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtho.2024.12.020_bib312","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-020-57812-2","article-title":"MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab","volume":"10","author":"Jing","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib313","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejso.2014.04.017","article-title":"MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients","volume":"40","author":"Su","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib314","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib315","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1073\/pnas.78.2.1219","article-title":"Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme","volume":"78","author":"Kamatani","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib316","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJM198508013130503","article-title":"Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9","volume":"313","author":"Chilcote","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib317","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib318","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav7769","article-title":"Nutrient availability shapes methionine metabolism in p16\/MTAP-deleted cells","volume":"5","author":"Sanderson","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.jtho.2024.12.020_bib319","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1038\/sj.onc.1209046","article-title":"SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation","volume":"24","author":"Ahuja","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2024.12.020_bib320","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/icb.2012.15","article-title":"Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses","volume":"90","author":"Hertzog","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib321","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023641","article-title":"Metabolomic profile of hepatitis C virus-infected hepatocytes","volume":"6","author":"Roe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib322","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1158\/1078-0432.CCR-21-3025","article-title":"Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA study): a phase II study with biomarker analysis","volume":"28","author":"Kao","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib323","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib324","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza","year":"2023","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib325","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1200\/JCO.23.00363","article-title":"Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm Phase II trial SAKK 06\/17","volume":"41","author":"Cathomas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib326","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.8153634","article-title":"A cell cycle regulator potentially involved in genesis of many tumor types","volume":"264","author":"Kamb","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib327","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.3390\/cancers13215313","article-title":"3p arm loss and survival in head and neck cancer: an analysis of TCGA dataset","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2024.12.020_bib328","first-page":"1702","article-title":"Predicting cancer development in oral leukoplakia: ten years of translational research","volume":"6","author":"Lee","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib329","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials","volume":"33","author":"Schwaederle","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib330","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1158\/2767-9764.CRC-24-0352","article-title":"Poor prognosis among radiation-associated bladder cancer is defined by clinicogenomic features","volume":"4","author":"Wijetunga","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib331","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/jmedgenet-2018-105610","article-title":"Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations","volume":"57","author":"Helgadottir","year":"2020","journal-title":"J Med Genet"},{"key":"10.1016\/j.jtho.2024.12.020_bib332","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230306","article-title":"Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations","volume":"15","author":"DeLeon","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtho.2024.12.020_bib333","doi-asserted-by":"crossref","first-page":"507","DOI":"10.21037\/jtd-23-1017","article-title":"Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function","volume":"16","author":"Zhao","year":"2024","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtho.2024.12.020_bib334","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e20628","article-title":"CDKN2A\/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: a next-generation-sequencing approach","volume":"37","author":"Giusti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib335","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","article-title":"CDKN2A alterations and response to immunotherapy in solid tumors","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib336","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/1759-7714.15326","article-title":"Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival","volume":"15","author":"Nie","year":"2024","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib337","article-title":"Integrative analysis of the genomic and immune microenvironment characteristics associated with clear cell renal cell carcinoma progression: implications for prognosis and immunotherapy","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib346","article-title":"Genomic alteration of MTAP\/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in RCC","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib338","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib339","doi-asserted-by":"crossref","first-page":"8383","DOI":"10.1038\/s41467-023-44159-1","article-title":"Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort","volume":"14","author":"Fukagawa","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib340","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative clinical and molecular characterization of translocation renal cell carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jtho.2024.12.020_bib341","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib342","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib343","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/atm.2019.10.54","article-title":"Relevance of arm somatic copy number alterations for oncologic outcomes and tumor immune microenvironment in clear cell renal cell carcinoma","volume":"7","author":"Xiong","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib344","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","article-title":"Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures","volume":"17","author":"\u015eenbabao\u011flu","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib345","article-title":"Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states","volume":"4","author":"Nyman","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib347","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13073-022-01146-3","article-title":"Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape","volume":"14","author":"Golkaram","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib348","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2024.12.020_bib349","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib350","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-15-2547","article-title":"Functional genomics uncover the biology behind the responsiveness of head and neck squamous cell cancer patients to cetuximab","volume":"22","author":"Bossi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib351","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105756","article-title":"Biological properties of hypoxia-related gene expression models\/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials","volume":"126","author":"Lenoci","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib352","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ccell.2015.12.007","article-title":"Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia","volume":"29","author":"Cheung","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib353","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.chembiol.2015.08.007","article-title":"KDM4\/JMJD2 histone demethylase inhibitors block prostate tumor growth by suppressing the expression of AR and BMYB-regulated genes","volume":"22","author":"Duan","year":"2015","journal-title":"Chem Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib354","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1101\/gr.156141.113","article-title":"Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth","volume":"24","author":"Gregory","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib355","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41419-020-03380-2","article-title":"Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc","volume":"12","author":"Lee","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jtho.2024.12.020_bib356","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib357","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1425282","article-title":"Unveiling the multifaceted antitumor effects of interleukin 33","volume":"15","author":"Arrizabalaga","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib358","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1002\/cam4.934","article-title":"CXCL9: evidence and contradictions for its role in tumor progression","volume":"5","author":"Ding","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib359","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112205","article-title":"Enhancing antitumor immunity and achieving tumor eradication with IL11RA mRNA immunotherapy","volume":"134","author":"Ur Rehman","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jtho.2024.12.020_bib360","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/2159-8290.CD-19-1366","article-title":"Immune surveillance in clinical regression of preinvasive squamous cell lung cancer","volume":"10","author":"Pennycuick","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib361","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1017\/erm.2022.28","article-title":"Roles of CCR10\/CCL27-CCL28 axis in tumour development: mechanisms, diagnostic and therapeutic approaches, and perspectives","volume":"24","author":"Mergia Terefe","year":"2022","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib362","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1776060","article-title":"Serum CCL27 predicts the response to bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer","volume":"9","author":"Zhong","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2024.12.020_bib363","doi-asserted-by":"crossref","first-page":"19055","DOI":"10.1073\/pnas.0705673104","article-title":"Tumor immune escape by the loss of homeostatic chemokine expression","volume":"104","author":"Pivarcsi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib364","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abk1692","article-title":"Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy","volume":"7","author":"Hoch","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib365","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq6509","article-title":"CXCL9 and CXCL10 bring the heat to tumors","volume":"7","author":"Reschke","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib366","article-title":"CDKN2A deletion in melanoma excludes T cell infiltration by repressing chemokine expression in a cell cycle-dependent manner","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib367","article-title":"From karyotypes to precision genomics in 9p deletion and duplication syndromes","volume":"3","author":"Sams","year":"2021","journal-title":"HGG Adv"},{"key":"10.1016\/j.jtho.2024.12.020_bib368","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41596-024-00953-9","article-title":"Engineering megabase-sized genomic deletions with MACHETE (Molecular Alteration of Chromosomes with Engineered Tandem Elements)","volume":"19","author":"Barriga","year":"2024","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jtho.2024.12.020_bib369","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.21037\/tau-23-649","article-title":"LncRNA ZFHX4-AS1 as a novel biomarker in adrenocortical carcinoma","volume":"13","author":"Chen","year":"2024","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.jtho.2024.12.020_bib370","article-title":"Novel LncRNA ZFHX4-AS1 as a potential prognostic biomarker that affects the immune microenvironment in ovarian cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib371","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anireprosci.2018.05.003","article-title":"Interferon epsilon is constitutively expressed in equine endometrium and up-regulated during the luteal phase","volume":"195","author":"Fischer","year":"2018","journal-title":"Anim Reprod Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib372","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2024.12.020_bib373","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib374","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2017.11.019","article-title":"TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer","volume":"33","author":"de Mingo Pulido","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib375","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garc\u00eda","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib376","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib377","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib378","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib379","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine Receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib380","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105822","article-title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis","volume":"161","author":"Arger","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib381","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib382","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib383","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib384","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1078-0432.CCR-19-2803","article-title":"A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer","volume":"26","author":"Romero","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib385","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib386","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib387","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1023\/A:1006659211340","article-title":"Chemokines and dendritic cell traffic","volume":"20","author":"Sozzani","year":"2000","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib388","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/0470856734.ch18","article-title":"In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity","volume":"256","author":"Vicari","year":"2004","journal-title":"Novartis Found Symp"},{"key":"10.1016\/j.jtho.2024.12.020_bib389","article-title":"Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer","volume":"4","author":"Lu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib390","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41577-018-0117-0","article-title":"DNA-stimulated cell death: implications for host defence, inflammatory diseases and cancer","volume":"19","author":"Paludan","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib391","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib392","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","article-title":"Dendritic cell-based cancer vaccines","volume":"200","author":"Santos","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib393","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib394","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib395","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1172\/JCI128562","article-title":"In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors","volume":"129","author":"Khalil","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtho.2024.12.020_bib396","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib397","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1089\/104303403322495025","article-title":"Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma","volume":"14","author":"Sharma","year":"2003","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtho.2024.12.020_bib398","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/10430340050016157","article-title":"Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication","volume":"11","author":"Miller","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtho.2024.12.020_bib399","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1479-5876-6-38","article-title":"Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer","volume":"6","author":"Baratelli","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib400","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/0008-5472.CAN-05-3619","article-title":"Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib401","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1158\/1078-0432.CCR-03-0380","article-title":"Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity","volume":"10","author":"Yang","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib402","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","article-title":"Phase I trial of intratumoral injection of CCL21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib403","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nri2297","article-title":"CCR7 and its ligands: balancing immunity and tolerance","volume":"8","author":"F\u00f6rster","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib404","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1189\/jlb.2MR0815-380R","article-title":"Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes","volume":"99","author":"Hauser","year":"2016","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jtho.2024.12.020_bib405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-2-22","article-title":"SLC\/CCL21-mediated anti-tumor responses require IFNgamma, MIG\/CXCL9 and IP-10\/CXCL10","volume":"2","author":"Sharma","year":"2003","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib406","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.immuni.2005.02.010","article-title":"CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells","volume":"22","author":"Marsland","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib407","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-4598-2-35","article-title":"Overexpression of CCL-21\/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells","volume":"2","author":"Riedl","year":"2003","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib408","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006896","article-title":"CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity","volume":"11","author":"Salehi-Rad","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib409","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.immuni.2015.05.018","article-title":"GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells","volume":"42","author":"Helft","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib410","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.4049\/jimmunol.1401243","article-title":"Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells","volume":"193","author":"Balan","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib411","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4049\/jimmunol.2100094","article-title":"Single-cell analysis reveals the heterogeneity of monocyte-derived and peripheral Type-2 conventional dendritic cells","volume":"207","author":"Gao","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib423","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2024.12.020_bib412","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib413","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.immuni.2013.07.008","article-title":"The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures","volume":"39","author":"Galon","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.jtho.2024.12.020_bib414","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41590-024-01960-4","article-title":"The complexity of immune evasion mechanisms throughout the metastatic cascade","volume":"25","author":"Haynes","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib415","doi-asserted-by":"crossref","first-page":"671","DOI":"10.7150\/ijbs.95723","article-title":"FAT1 knockdown enhances the CSC properties of HNSCC through p-CaMKII-mediated inactivation of the IFN pathway","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jtho.2024.12.020_bib416","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","article-title":"EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer","volume":"1","author":"Gong","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2024.12.020_bib417","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2402913121","article-title":"Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors","volume":"121","author":"Fern\u00e1ndez-Garc\u00eda","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2024.12.020_bib418","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41590-024-02014-5","article-title":"A STAT3-STING-IFN axis controls the metastatic spread of small cell lung cancer","volume":"25","author":"Guanizo","year":"2024","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib419","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/1535-7163.MCT-24-0435","article-title":"Characteristics of a CCL21 gene-modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer","volume":"24","author":"Oh","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jtho.2024.12.020_bib420","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41467-020-14987-6","article-title":"Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours","volume":"11","author":"Brenner","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib422","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0152","article-title":"Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma","volume":"12","author":"Kalbasi","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2024.12.020_bib421","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma","volume":"13","author":"Chow","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib427","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-20-0672","article-title":"Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor response","volume":"11","author":"Montesion","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2024.12.020_bib428","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jtho.2019.02.008","article-title":"PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer","volume":"14","author":"Negrao","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2024.12.020_bib424","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1016\/j.cell.2023.03.029","article-title":"KaryoCreate: a CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres","volume":"186","author":"Bosco","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib429","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41467-022-29203-w","article-title":"A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity","volume":"13","author":"Pyke","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2024.12.020_bib425","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg4521","article-title":"Oncogene-like addiction to aneuploidy in human cancers","volume":"381","author":"Girish","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.jtho.2024.12.020_bib430","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1474-9726.2012.00871.x","article-title":"Review: a meta-analysis of GWAS and age-associated diseases","volume":"11","author":"Jeck","year":"2012","journal-title":"Aging Cell"},{"key":"10.1016\/j.jtho.2024.12.020_bib431","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/0008-5472.CAN-09-0145","article-title":"Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma","volume":"69","author":"Kadariya","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2024.12.020_bib426","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10875-021-01153-w","article-title":"Partial trisomy 9p with clinical symptoms resembling Interferonopathies","volume":"42","author":"Inoue","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jtho.2024.12.020_bib118","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41467-017-01355-0","article-title":"Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors","volume":"8","author":"Cheng","year":"2017","journal-title":"Nat Commun"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086424025395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:19:08Z","timestamp":1788232748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086424025395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":431,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1556086424025395"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.020","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9\/10 Induction","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2024.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}